# Airway Lung Stent Market

> Airway Lung Stent Market Research Report: Size, Share, Trend Analysis By Stent Material (Nitinol, Silicone, Polyurethane, Polytetrafluoroethylene (PTFE), Stainless Steel), By Stent Design (Single-Flanged Stents, Double-Flanged Stents, Palmaz-Schatz Stents, Wallstents, Cavitron Ultra Stents), By Stent Function (Bronchial Stent, Tracheal Stent, Esophageal Stent), By Delivery Method (Rigid Bronchoscopy, Flexible Bronchoscopy, Tracheostomy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.95%
- **2025:** USD 241.9 Million
- **2035:** USD 473.6 Million
- **Key Players:** Boston Scientific Corporation, Merit Medical Systems, Inc., Olympus Corporation, Novatech SA, Efer Endoscopy, M.I.Tech Co., Ltd., Micro-Tech (Nanjing) Co., Ltd., ELLA-CS, s.r.o.

**Report ID:** MRFR/HC/7389-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** November 04, 2026

**URL:** https://www.marketresearchfuture.com/reports/airway-lung-stent-market-8861

---

## Market Summary

## Airway Lung Stent Market Summary

The airway [lung stent](https://www.marketresearchfuture.com/reports/lung-stent-market-33081) market was valued at USD 241.9 Million in 2025 and is projected to reach USD 258.7 Million in 2026, rising to USD 473.6 Million by 2035 at a CAGR of 6.95% over 2026–2035. Demand rests on a large and growing oncology caseload: lung cancer produced roughly 2.5 million new cases and 1.8 million deaths worldwide in 2022 [1], and a meaningful fraction of those patients develop central airway narrowing that needs mechanical support. Regulatory activity has also picked up, with several tracheobronchial devices cleared or authorized by the U.S. FDA between 2023 and 2024 [6][7][8].

Product technology is shifting in a clear direction. Bare and partially covered metal stents, once the default for malignant disease, are giving ground to fully covered nitinol designs, Dumon-style silicone devices, patient-specific 3D-printed implants, and resorbable polymer scaffolds that avoid a second removal procedure. A pivotal FDA trial of a 3D-printed resorbable tracheobronchial splint opened in January 2025 with a target enrollment of at least 35 children [9], signalling that personalized airway support is moving from compassionate use toward routine approval.

North America leads the airway lung stent market with a 41.8% revenue share in 2025, supported by dense [bronchoscopy](https://www.marketresearchfuture.com/reports/bronchoscopy-market-11508) infrastructure and established reimbursement. Asia-Pacific is the fastest-growing region at an 8.9% CAGR, driven by China's lung cancer burden and expanding tertiary hospital capacity. Europe ranks second at USD 66.8 Million, anchored by Germany and France's long tradition of silicone stenting. Over the next decade, procedure migration to outpatient settings and custom devices will reshape where and how stents are placed.

## Key Report Takeaways

### • By Product

- Self-Expandable Stents held 62.8% of the airway lung stent market in 2025, reflecting their ease of deployment through a flexible bronchoscope.
- Non-Expandable / Customized 3D-Printed Stents are forecast to post a 9.40% CAGR through 2035 as hospital printing labs mature.
- Balloon-Expandable Stents generated USD 54.2 Million in 2025, concentrated in pediatric and short-segment stenosis cases.

### • By Material

- Metal accounted for 54.1% of 2025 revenue, owing to its radial strength in fast-progressing tumors.
- Bioresorbable Polymers are the fastest-rising material at a 9.70% CAGR, as clinicians favor temporary support without removal surgery.

### • By Type

- Tracheobronchial Stents captured 69.9% of 2025 revenue across central airway applications.
- Y-Shaped Carinal Stents are set to grow at a 9.25% CAGR, driven by bifurcation complications after lung transplantation.

### • By Indication

- Malignant Central Airway Obstruction represented 57.2% of 2025 demand in the airway lung stent market.
- Post-Lung-Transplant Airway Complications form the fastest-growing indication at a 9.95% CAGR.

### • By End User

- Hospitals retained a 70.6% share in 2025, supported by intensive care backup and [thoracic surgery](https://www.marketresearchfuture.com/reports/thoracic-surgery-market-27902) teams.
- Specialty Pulmonology Clinics are projected to expand at a 10.75% CAGR as outpatient bronchoscopy scales.

### • By Region

- North America held a 41.8% share in 2025, led by the United States.
- Asia-Pacific is forecast to grow at an 8.9% CAGR, the highest of any region.
- Europe contributed USD 66.8 Million in 2025.

## Market Size and Forecast (2021–2035)

Estimates for the airway lung stent market combine bottom-up procedure modelling with top-down validation. Procedure volumes were built from lung cancer incidence [1][2], transplant registry data [3], and tuberculosis burden [15], then multiplied by device penetration rates and regional average selling prices gathered through interviews with interventional bronchoscopists, hospital procurement teams, and distributors. Company filings [19][21] and regulatory databases [6][8] were used to cross-check revenue pools and product mix.

## Market Drivers

## Driver Impact Analysis

Impact percentages below are directional estimates of each driver's contribution to the forecast CAGR. They overlap and interact, so they should not be summed to reproduce the headline growth rate.

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising lung cancer incidence and central airway obstruction | +2.1% | Global, strongest in Asia-Pacific | Long-term (≥4 yr) | [1][2] |
| Growth in lung transplant volumes | +0.9% | North America, Europe | Medium-term (2–4 yr) | [3][4] |
| Adoption of patient-specific 3D-printed stents | +1.0% | North America, Europe | Medium-term (2–4 yr) | [9][14] |
| Clinical acceptance of resorbable polymer stents | +0.8% | Europe, Asia-Pacific | Long-term (≥4 yr) | [9] |
| Expansion of bronchoscopy capacity in emerging economies | +1.1% | China, India, GCC | Medium-term (2–4 yr) | [17] |
| Post-tuberculosis bronchial stenosis caseload | +0.5% | India, South Asia, Africa | Long-term (≥4 yr) | [15] |
| Steady stream of regulatory clearances | +0.6% | United States | Short-term (≤2 yr) | [6][7][8] |

### Rising Lung Cancer Incidence and Central Airway Obstruction

With over 2.5 million new cases in 2022, lung cancer continued to be the most frequently diagnosed cancer worldwide [1]. Clinical research shows, between 20 and 30 percent of individuals with lung cancer had central airway involvement at some point in their illness. When stenting and tumor debulking are coupled, the technical success rate for therapeutic bronchoscopy is over 90%, registry data showed [13]. Because of this data base, thoracic oncology regimens continue to incorporate palliative stenting, providing a sizable, recurrent treatment pool for the airway lung stent industry.

### Growth in Lung Transplant Volumes

The national transplant registry showed, U.S. programs currently execute well over 2,500 lung transplants annually [3]. The ISHLT 2018 consensus statement standardized the classification and management of airway problems, including as bronchomalacia and anastomotic stenosis, which affect a significant proportion of recipients [4]. Longer graft lifespan increases the window of opportunity for recurrent interventions, and uniform definitions assist pulmonologists in justifying stent insertion.

### Adoption of Patient-Specific 3D-Printed Stents

Standard stents come in limited sizes, and poor fit drives granulation, mucus plugging, and displacement. The FDA's clearance of patient-specific silicone airway stents developed at Cleveland Clinic established a regulatory route for CT-derived designs; that institution estimated around 30,000 airway stents were implanted in the U.S. in 2020 [14]. Point-of-care printing labs now shorten turnaround to days, making personalized stents practical for complex anatomy.

### Clinical Acceptance of Resorbable Polymer Stents

Resorbable implants remove the need for retrieval, which matters in benign disease where stents are temporary. Michigan Medicine and Materialise opened an FDA pivotal trial in January 2025 for a 3D-printed polycaprolactone tracheobronchial splint, enrolling at least 35 children over eight years [9]. Positive results would validate resorbable airway devices for wider labelling and draw adult indications into development pipelines.

### Expansion of Bronchoscopy Capacity in Emerging Economies

China recorded more than one million new lung cancer cases in 2022 [2], and provincial procurement reforms are broadening access to endoscopic consumables [17]. India's Production Linked Incentive scheme for medical devices carries an outlay of INR 3,420 crore to build domestic manufacturing. Both trends add trained operators, procedure rooms, and lower-cost device supply across high-burden markets.

### Post-Tuberculosis Bronchial Stenosis Caseload

The WHO reported about 10.8 million new tuberculosis cases in 2023 [15]. Endobronchial tuberculosis frequently heals with fibrotic narrowing, and silicone or angulated stents are standard options when balloon dilation fails. High-burden countries such as India, Indonesia, and South Africa therefore carry a benign stenosis pool largely independent of oncology trends.

### Steady Stream of Regulatory Clearances

The FDA cleared an updated Ultraflex tracheobronchial system in July 2023 [6], authorized the amnion-covered AMStent through De Novo review in October 2024 [7], and cleared a new Dumon silicone stent in October 2024 [8]. Each clearance widens surgeons' options and refreshes sales-force messaging, supporting near-term airway lung stent market revenue in the United States.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Stent-related complications and removal burden | −0.9% | Global | Long-term (≥4 yr) | [5][13] |
| FDA safety communication legacy on metal stents in benign disease | −0.5% | North America | Medium-term (2–4 yr) | [5] |
| EU MDR recertification cost and portfolio rationalization | −0.6% | Europe | Short-term (≤2 yr) | [11][12] |
| Limited trained interventional operators | −0.7% | Asia-Pacific, South America, MEA | Long-term (≥4 yr) | [22] |
| Reimbursement and price pressure | −0.5% | Europe, China | Medium-term (2–4 yr) | [16][17] |

### Stent-Related Complications and Removal Burden

Repeat bronchoscopy is still frequently necessary due to granulation tissue, mucus impaction, displacement, and fracture. Complications increase with dwell time, registry experience with neoplastic obstruction highlighted [13]. Because each revision treatment increases patient risk and expense, several centers save stenting for situations in which dilation or ablation are insufficient.

### Legacy Caution on Metal Stents in Benign Disease

Due to their challenging removal, the FDA recommended against the routine use of metallic tracheal stents in benign airway problems in a 2005 public health notification [5]. Hospital procedures are still shaped by the direction twenty years later. The addressable pool for more expensive metal devices is limited since clinicians still choose silicone for mild stenosis.

### EU MDR Recertification Cost

Regulation (EU) 2017/745 raised clinical evidence requirements for implantable devices [12]. Although Regulation (EU) 2023/607 extended transition deadlines to 2027–2028 [11], smaller manufacturers face notified-body backlogs and recertification fees. Some low-volume airway sizes may be withdrawn rather than recertified, narrowing physician choice in Europe.

### Limited Trained Interventional Operators

Stent placement, particularly through a rigid scope, requires specialized training that remains concentrated in academic centers. Health spending per capita in many low- and middle-income countries stays far below OECD levels [22], restricting investment in bronchoscopy suites and fellowship programs.

### Reimbursement and Price Pressure

Bundled hospital payments in the U.S. outpatient system [16] and centralized procurement in China [17] compress device margins. Tender-driven purchasing in parts of Europe has a similar effect, pushing suppliers to justify premium covered and custom designs with outcome data.

## Opportunities

## Airway Lung Stent Market Opportunities

### Emerging-Market Capacity in India and Southeast Asia

India combines a high tuberculosis burden [15] with rising lung cancer diagnoses and a government-backed device manufacturing push. Local production of silicone and nitinol stents could cut landed costs sharply, opening tier-2 city hospitals to routine stenting. Suppliers that pair low-cost products with training partnerships stand to capture early share.

### Design-as-a-Service and Imaging Data Platforms

Patient-specific stents create a new business model: hospitals upload CT data, and a vendor returns a printed device plus planning files. Recurring software fees, design royalties, and anonymized anatomical datasets can lift the value captured per case in the airway lung stent market. FDA-cleared patient-specific workflows [14] provide the regulatory template.

### Pediatric Airway Devices

Infant tracheobronchomalacia has few approved options, and the ongoing pivotal trial of a resorbable splint [9] could open a dedicated pediatric category. Growth-accommodating designs would command premium pricing in a segment with limited competition.

### Transplant-Focused Bifurcation Devices

Rising transplant volumes [3] and ISHLT grading standards [4] create demand for Y-shaped and angulated stents built for post-anastomotic anatomy. Device makers that publish transplant-specific outcome data can win formulary positions at high-volume centers.

### Drug-Eluting and Bioactive Coatings

Coatings that limit granulation could reduce revision rates, addressing the main clinical restraint. The amnion-covered AMStent authorization [7] shows regulators will accept biologically active coverings, inviting further work on anti-proliferative and antimicrobial layers.

## Future Outlook

## Airway Lung Stent Market Future Outlook

### AI-Assisted Planning and Navigation

CT segmentation software increasingly automates airway measurement, reducing the engineering time behind custom stent design. As AI-assisted planning merges with robotic and navigational bronchoscopy, sizing errors should fall and first-pass placement success should rise. Vendors that bundle planning software with devices will hold a data advantage across the decade.

### Point-of-Care Manufacturing

Hospital-based printing facilities, such as the clean-room operation Materialise established near Michigan's hospital for its trial [9], point toward decentralized production. By the early 2030s, large academic centers may print silicone and polymer stents on site, shortening lead times from weeks to days and shifting value from inventory to design services.

### Oncology Burden and Demographic Pressure

Global cancer cases are projected to rise to about 35 million by 2050, up roughly 77% from 2022 levels [1]. Lung cancer will remain a leading contributor, and aging populations in Japan, Europe, and China will add frail patients for whom stenting is preferable to open surgery. This sustains palliative demand in the airway lung stent market through 2035.

### Value-Based Procurement and Outcome Evidence

Payers and procurement agencies are asking for evidence on revision rates, hospital stay, and quality of life [16][17]. Manufacturers that fund registries and publish comparative outcomes will defend premium pricing, while commodity uncovered stents face continued erosion. Evidence generation will become a core competitive capability in the airway lung stent market.

## Segment Insights

## Airway Lung Stent Market Segmentation

### By Product

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Self-Expandable Stents | 62.8% share | Flexible bronchoscope deployment and steady radial force |
| Balloon-Expandable Stents | USD 54.2 Million | Precise sizing in pediatric and short-segment stenosis |
| Non-Expandable / Customized 3D-Printed Stents | 9.40% CAGR (2026–2035) | Complex anatomy and hospital printing labs |

Within the airway lung stent market, Self-Expandable Stents lead because they deploy quickly, conform to variable diameters, and suit both malignant and benign cases. Balloon-Expandable Stents serve narrow niches where exact diameter control matters, especially in children. Non-Expandable / Customized 3D-Printed Stents grow fastest, as CT-derived designs address airways distorted by tumors or surgery that off-the-shelf products fit poorly.

### By Material

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Metal | 54.1% share | Radial strength and radiopacity in malignant disease |
| Silicone | USD 68.9 Million | Easy removal in benign stenosis |
| Hybrid (Covered / Composite) | 7.6% CAGR (2026–2035) | Tumor ingrowth prevention with metal frames |
| Bioresorbable Polymers | 9.70% CAGR (2026–2035) | No retrieval procedure required |

Material choice in the airway lung stent market tracks indication closely. Metal leads in malignant obstruction, where radial strength and imaging visibility matter most. Silicone remains the benign-disease standard because it can be removed easily. Hybrid (Covered / Composite) designs combine metal skeletons with polymer membranes to block ingrowth, while Bioresorbable Polymers grow fastest as pediatric and benign trials build evidence for temporary support.

### By Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Tracheobronchial Stents | 69.9% share | Broad use across trachea and main bronchi |
| Laryngeal Stents | USD 32.7 Million | Post-trauma and post-resection upper airway support |
| Y-Shaped Carinal Stents | 9.25% CAGR (2026–2035) | Bifurcation complications after transplant |

Across the airway lung stent market, Tracheobronchial Stents dominate because they treat the most common sites of tumor compression and post-intubation stenosis. Laryngeal Stents address upper-airway collapse after trauma or head-and-neck surgery, a smaller but stable niche. Y-Shaped Carinal Stents grow fastest, driven by transplant recipients and carinal tumors where straight devices migrate or leave a branch unsupported.

### By Indication

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Malignant Central Airway Obstruction | 57.2% share | Palliation in advanced lung and esophageal cancer |
| Benign Tracheal Stenosis | USD 60.5 Million | Post-intubation and post-tuberculosis scarring |
| Post-Lung-Transplant Airway Complications | 9.95% CAGR (2026–2035) | Rising transplant volumes and graft survival |
| Tracheoesophageal Fistula | 6.4% CAGR (2026–2035) | Covered stents sealing airway-esophageal leaks |

The airway lung stent market remains anchored in Malignant Central Airway Obstruction, where restoring airflow delivers immediate symptom relief. Benign Tracheal Stenosis provides steady volume and increasingly uses silicone or resorbable devices. Post-Lung-Transplant Airway Complications grow fastest as transplant numbers rise [3], and Tracheoesophageal Fistula requires covered designs, often paired with an esophageal stent.

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 70.6% share | ICU backup and thoracic surgery availability |
| Ambulatory Surgical Centers | USD 44.5 Million | Lower facility cost for planned procedures |
| Specialty Pulmonology Clinics | 10.75% CAGR (2026–2035) | Outpatient flexible bronchoscopy growth |

Hospitals hold most of the airway lung stent market because urgent obstruction cases need anesthesia, intensive care, and surgical backup on site. Ambulatory Surgical Centers take planned exchanges and elective benign cases at lower facility cost. Specialty Pulmonology Clinics expand fastest as flexible bronchoscopy and short-stay protocols allow selected stent placements outside the hospital.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.8% share | Covered nitinol stents, patient-specific devices, transplant programs |
| Europe | USD 66.8 Million | Silicone stent tradition, MDR recertification, resorbable trials |
| Asia-Pacific | 8.9% CAGR (2026–2035) | Lung cancer burden, hospital expansion, local manufacturing |
| Middle East and Africa | USD 10.4 Million | GCC tertiary care investment, TB-related stenosis |
| South America | 5.1% share | Public hospital tenders, oncology center growth |
| Total | USD 241.9 Million | — |

The airway lung stent market shows a clear regional hierarchy, with mature Western markets holding most revenue and Asia-Pacific supplying the fastest growth.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 86.5% of regional revenue | Large transplant volumes and frequent FDA clearances |
| Canada | USD 9.5 Million | Provincial thoracic oncology centers |
| Mexico | 8.2% CAGR (2026–2035) | Private hospital expansion in major cities |

U.S. hospitals dominate regional demand, drawing on the world's largest lung transplant program [3] with a regulatory pipeline that delivered three notable airway device authorizations in 2023–2024 [6][7][8]. Patient-specific stent workflows originated at U.S. academic centers [14], giving domestic hospitals early access to custom devices. Canada relies on provincially funded thoracic centers with deliberate adoption cycles, while Mexico's growth stems from private hospital networks adding interventional pulmonology services in Mexico City, Monterrey, and Guadalajara.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.8% of regional revenue | High bronchoscopy volumes and strong reimbursement |
| United Kingdom | USD 11.8 Million | NHS lung cancer screening expansion |
| France | 6.6% CAGR (2026–2035) | Home market of silicone stent manufacturers |
| Italy | 13.2% of regional revenue | Established interventional centers in northern regions |
| Spain | USD 7.0 Million | Growing transplant activity |
| Rest of Europe | 5.9% CAGR (2026–2035) | Gradual adoption in Central and Eastern Europe |

Germany anchors European demand through high procedure volumes and DRG coding that recognizes complex bronchoscopic interventions. France hosts silicone stent producers and a long clinical tradition in rigid techniques, while the UK's targeted lung health checks are lifting early diagnosis rates. MDR recertification [11][12] remains the region's main supply-side risk, potentially thinning low-volume product lines through 2028.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 38.5% of regional revenue | Over one million annual lung cancer cases |
| Japan | USD 12.6 Million | Aging population and advanced endoscopy |
| India | 11.2% CAGR (2026–2035) | TB-related stenosis and PLI-backed manufacturing |
| Australia | 6.8% of regional revenue | Specialist transplant and thoracic units |
| South Korea | USD 3.7 Million | Domestic metallic stent manufacturing base |
| Rest of Asia-Pacific | 8.1% CAGR (2026–2035) | Hospital build-out in Southeast Asia |

China's scale within the airway lung stent market is unmatched, with lung cancer incidence exceeding one million new cases in 2022 [2]. Volume-based procurement [17] is lowering prices while expanding access. Korea's manufacturing strength drew Olympus to acquire Taewoong Medical for about USD 370 million in a deal closed in January 2024 [10]. India offers the region's fastest country growth, supported by its tuberculosis burden [15] and incentive-backed domestic production.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 46.2% of regional revenue | Government investment in tertiary and transplant care |
| South Africa | USD 2.3 Million | Post-tuberculosis airway disease |
| Rest of Middle East and Africa | 7.4% CAGR (2026–2035) | Gradual expansion of bronchoscopy services |

GCC states, led by Saudi Arabia under its Vision 2030 health transformation program [23], are funding specialist hospitals and recruiting interventional pulmonologists. South Africa's demand is shaped by one of the world's highest tuberculosis burdens [15], which generates benign stenosis cases. Elsewhere in the region, access remains confined to a few referral centers.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 54.6% of regional revenue | Large public oncology network and private hospital chains |
| Argentina | USD 2.1 Million | Academic thoracic surgery centers |
| Rest of South America | 6.9% CAGR (2026–2035) | Oncology center development in Chile, Colombia, and Peru |

Brazil leads regional consumption through both its public health system and private hospital groups in São Paulo and Rio de Janeiro. Currency volatility makes imported nitinol devices expensive, favoring silicone stents in Argentina and smaller markets. Public tenders dominate purchasing, so price-competitive suppliers hold an advantage.

## Competitive Benchmarking

## Competitive Benchmarking

The airway lung stent market is moderately concentrated, with an estimated HHI of 1,200–1,450 and the top five suppliers holding roughly 55–62% of revenue. Large diversified medtech firms compete on covered metal stents and distribution reach, while specialist manufacturers in France, Korea, and Japan defend silicone and nitinol niches. Patient-specific designers and resorbable-device developers form a third tier that is small today but growing quickly.

| Company | Est. Revenue Share Range | Key Offerings for airway lung stent market | Strategic Positioning |
| --- | --- | --- | --- |
| Boston Scientific Corporation | ~16–20% | Ultraflex tracheobronchial stent systems | Global reach and FDA-cleared covered metal platform |
| Merit Medical Systems, Inc. | ~13–17% | AERO and AEROmini covered tracheobronchial stents | Fully covered nitinol designs for malignant strictures |
| Olympus Corporation | ~10–13% | Endoscopy systems and Taewoong Niti-S metallic stents | Bundles stents with bronchoscopy installed base |
| Novatech SA | ~8–11% | Dumon silicone stents including Y-configurations | Benchmark silicone portfolio for rigid bronchoscopy |
| Efer Endoscopy | ~4–6% | Rigid bronchoscopes and silicone stents | Specialist supplier to interventional centers |
| M.I.Tech Co., Ltd. | ~4–6% | Hanarostent tracheobronchial stents | Cost-competitive Korean nitinol manufacturer |
| Micro-Tech (Nanjing) Co., Ltd. | ~3–5% | Covered metal airway stents | Strong position in Chinese procurement |
| ELLA-CS, s.r.o. | ~3–5% | Metal and biodegradable stents | Early mover in resorbable stent technology |
| Fuji Systems Corporation | ~2–4% | Silicone tracheobronchial stents | Leading Japanese silicone supplier |
| VisionAir Solutions | ~1–2% | Patient-specific 3D-designed airway stents | Pioneer of CT-based custom airway devices |

## Recent News & Developments

## Recent News & Developments

- U.S. FDA / Boston Scientific (July 2023): The FDA cleared an updated Ultraflex Tracheobronchial Stent System through the 510(k) pathway, refreshing a widely used metal platform for malignant strictures [6].
- European Commission (March 2023): Regulation (EU) 2023/607 extended MDR transition periods to 2027–2028, easing near-term supply disruption for airway stent makers [11].
- Olympus Corporation (January 2024): Olympus closed its roughly USD 370 million acquisition of Korea's Taewoong Medical, adding a broad metallic stent portfolio and manufacturing base [10].
- IARC / WHO (February 2024): Updated global cancer statistics placed lung cancer as the most commonly diagnosed cancer in 2022, reinforcing long-term palliative stent demand [1].
- Peytant Solutions (October 2024): The FDA granted De Novo authorization for the AMStent amnion-covered tracheobronchial stent, a new biologically covered option for malignant obstruction [7].
- Novatech SA (October 2024): The FDA cleared the Tracheobronxane Dumon silicone stent, expanding U.S. silicone choices for benign and malignant disease [8].
- Michigan Medicine / Materialise (January 2025): A pivotal FDA trial of a 3D-printed resorbable tracheobronchial splint opened, targeting at least 35 children over eight years [9].

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Self-expandable, balloon-expandable, and custom airway stents in metal, silicone, hybrid, and resorbable materials used for malignant and benign airway disease across hospitals, ambulatory surgical centers, and pulmonology clinics |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 241.9 Million |
| Market Size in 2035 | USD 473.6 Million |
| CAGR (2026–2035) | 6.95% |
| Fastest Growing Segments | Specialty Pulmonology Clinics (10.75% CAGR); Post-Lung-Transplant Airway Complications (9.95% CAGR); Bioresorbable Polymers (9.70% CAGR); Non-Expandable / Customized 3D-Printed Stents (9.40% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Boston Scientific Corporation, Merit Medical Systems, Olympus Corporation, Novatech SA, Efer Endoscopy, M.I.Tech, Micro-Tech (Nanjing), ELLA-CS, Fuji Systems Corporation, VisionAir Solutions |
| Valuation Currency | USD Million |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What should hospitals weigh when buying devices in the airway lung stent market?**
A: Total episode cost matters more than unit price. A cheaper stent that triggers two revision bronchoscopies costs more overall, so buyers increasingly request vendor data on granulation and displacement rates [13].

**Q: How do silicone and metal stents differ for benign disease?**
A: In the airway lung stent market, silicone stents are removable and avoid tissue ingrowth, which suits temporary support. Metal stents embed into the airway wall over time, making later removal difficult, so most guidelines discourage them in benign stenosis [5].

**Q: Which investment themes look most attractive in the airway lung stent market?**
A: Patient-specific design platforms and resorbable materials offer the strongest differentiation. Both carry recurring software or design revenue and face fewer low-cost competitors than standard covered metal stents [9][14].

**Q: How does Breakthrough Device designation affect airway stent launches?**
A: Breakthrough status gives sponsors more frequent FDA interaction and priority review. It does not lower evidence standards, but it can shorten time to market for novel resorbable or bioactive airway devices by several months.

**Q: What integration challenges do clinics face when adopting custom stents?**
A: Custom stents require high-resolution CT protocols, secure image transfer to the designer, and a two-to-three-week planning cycle. Clinics without radiology workflow support often struggle to schedule placements before the patient's condition changes [14].

**Q: Is the airway lung stent market seeing new uses beyond the lung?**
A: Yes. Esophageal cancer with airway invasion and pediatric tracheobronchomalacia are expanding use cases. Combined airway-esophageal dual stenting is also gaining attention for complex fistulas [9].

**Q: How do group purchasing organizations shape supplier competition?**
A: Group purchasing organizations negotiate multi-year contracts that favor vendors offering full bronchoscopy portfolios. Smaller stent specialists often win access only through distribution partnerships with larger endoscopy suppliers [21].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/airway-lung-stent-market-8861*